Floatz logo

Jcar017 (Lisocabtagene Maraleucel)

High-Grade B-Cell Lymphoma, Nos

Fred Hutchinson Cancer CenterCell therapyPhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

89 Active assets in the High-Grade B-Cell Lymphoma, Nos cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Washington
Phase 3BB
Ifosfamide
University of California, Davis
Phase 3BB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 3BB
Inno-206
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Jcar017 (Lisocabtagene Maraleucel) is also rated in:

diffuse large B-cell lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
non-Hodgkin lymphomaDormant
BB
Indicative ·
65 / 100
View asset →
primary mediastinal large B-cell lymphomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →